# Epizyme Inc. (EPZM)

Source: https://www.quantisnow.com/company/EPZM
Generated: 2026-11-14T07:31:28.417Z

- Ticker: EPZM
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2013
- Website: epizyme.com

## About

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; and HUTCHMED (China) Limited. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

## Latest EPZM news and filings

- 2024-08-14 08:43 UTC [FDA Approval for TAZVERIK issued to EPIZYME INC](https://www.quantisnow.com/insight/fda-approval-for-tazverik-issued-to-epizyme-inc-5657878)
- 2023-11-17 09:37 UTC [FDA Approval for TAZVERIK issued to EPIZYME INC](https://www.quantisnow.com/insight/fda-approval-for-tazverik-issued-to-epizyme-inc-5091592)
- 2022-09-08 20:01 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Epizyme Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-epizyme-inc-amendment-3391014)
- 2022-09-02 14:27 UTC [Market Insight] [Looking Into Epizyme's Return On Capital Employed](https://www.quantisnow.com/insight/looking-into-epizymes-return-on-capital-employed-3369635)
- 2022-08-23 21:03 UTC [SEC Form 15-12G filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-epizyme-inc-3323938)
- 2022-08-17 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-epizyme-inc-3297840)
- 2022-08-17 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-epizyme-inc-3297816)
- 2022-08-17 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-epizyme-inc-3297813)
- 2022-08-16 23:03 UTC [SEC Form 4] [SEC Form 4: Giordano Michael F returned 17,054 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-giordano-michael-f-returned-17054-shares-to-3297209)
- 2022-08-16 23:02 UTC [SEC Form 4] [SEC Form 4: Goldfischer Carl returned 3,403,005 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-goldfischer-carl-returned-3403005-shares-to-the-3297206)
- 2022-08-16 23:02 UTC [SEC Form 4] [SEC Form 4: Conroy Kevin T returned 62,318 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-conroy-kevin-t-returned-62318-shares-to-3297204)
- 2022-08-16 22:59 UTC [SEC Form 4] [SEC Form 4: Richon Victoria returned 22,608 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-richon-victoria-returned-22608-shares-to-the-3297200)
- 2022-08-16 22:59 UTC [SEC Form 4] [SEC Form 4: Mott David M returned 8,994 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-mott-david-m-returned-8994-shares-to-3297193)
- 2022-08-16 22:58 UTC [SEC Form 4] [SEC Form 4: Beveridge, Roy A returned 46,037 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-beveridge-roy-a-returned-46037-shares-to-3297192)
- 2022-08-16 22:57 UTC [SEC Form 4] [SEC Form 4: Agarwal Shefali returned 286,539 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-agarwal-shefali-returned-286539-shares-to-the-3297189)
- 2022-08-16 22:55 UTC [SEC Form 4] [SEC Form 4 filed by Legorreta Pablo G.](https://www.quantisnow.com/insight/sec-form-4-filed-by-legorreta-pablo-g-3297183)
- 2022-08-16 22:55 UTC [SEC Form 4] [SEC Form 4 filed by Korn Jerald](https://www.quantisnow.com/insight/sec-form-4-filed-by-korn-jerald-3297182)
- 2022-08-16 22:55 UTC [SEC Form 4] [SEC Form 4: Beaulieu Joseph returned 52,076 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-beaulieu-joseph-returned-52076-shares-to-the-3297181)
- 2022-08-16 22:55 UTC [SEC Form 4] [SEC Form 4: Bate Kenneth returned 17,054 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-bate-kenneth-returned-17054-shares-to-the-3297180)
- 2022-08-16 22:54 UTC [SEC Form 4] [SEC Form 4: Kutok Jeffery returned 120,067 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-kutok-jeffery-returned-120067-shares-to-the-3297179)
- 2022-08-16 22:54 UTC [SEC Form 4] [SEC Form 4: Stuckley Carol returned 25,696 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-stuckley-carol-returned-25696-shares-to-the-3297177)
- 2022-08-16 22:52 UTC [SEC Form 4] [SEC Form 4: Bogle Grant C. returned 259,170 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-bogle-grant-c-returned-259170-shares-to-3297173)
- 2022-08-13 00:08 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-epizyme-inc-3282634)
- 2022-08-12 23:57 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-epizyme-inc-3282565)
- 2022-08-12 23:39 UTC [SEC Form POS AM filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-epizyme-inc-3282558)
- 2022-08-12 23:46 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-epizyme-inc-3282557)
- 2022-08-13 00:07 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-epizyme-inc-3282555)
- 2022-08-13 00:04 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-epizyme-inc-3282414)
- 2022-08-13 00:00 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-epizyme-inc-3282408)
- 2022-08-13 00:02 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-epizyme-inc-3282407)
- 2022-08-12 23:48 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-epizyme-inc-3282405)
- 2022-08-12 23:52 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-epizyme-inc-3282404)
- 2022-08-12 23:54 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-epizyme-inc-3282403)
- 2022-08-12 23:44 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-epizyme-inc-3282400)
- 2022-08-12 23:37 UTC [SEC Form POS AM filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-epizyme-inc-3282386)
- 2022-08-12 16:00 UTC [SEC Form 8-K] [Epizyme Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/epizyme-inc-filed-sec-form-8-k-termination-of-a-material-3278541)
- 2022-08-12 13:23 UTC [SEC Form 25-NSE filed by Epizyme Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-epizyme-inc-3277360)
- 2022-08-12 11:51 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by Epizyme Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-epizyme-inc-amendment-3276606)
- 2022-08-12 11:44 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by Epizyme Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-epizyme-inc-amendment-3276563)
- 2022-08-12 01:00 UTC [SEC Form 4] [SEC Form 4: Bogle Grant C. exercised 1,217,500 shares at a strike of $1.40 and covered exercise/tax liability with 1,141,390 shares, increasing direct ownership by 42% to 259,170 units](https://www.quantisnow.com/insight/sec-form-4-bogle-grant-c-exercised-1217500-shares-at-3275420)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/EPZM
- Earnings history: https://www.quantisnow.com/earnings/EPZM
- Dividend history: https://www.quantisnow.com/dividends/EPZM
- Insider transactions: https://www.quantisnow.com/insiders/EPZM
- Options chain: https://www.quantisnow.com/options/EPZM
- SEC 8-K filings only: https://www.quantisnow.com/company/EPZM/8-k
- RSS and alerts for EPZM: https://www.quantisnow.com/docs/rss-feeds.md